These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 18416173)

  • 1. [State of vasoregulative function of vascular endothelium and cardiohemodynamics in patients with chronic obstructive diseases of the lung (CODL) treated with losartan].
    Rodionova VV; Lysenko AO; Ruchko VI; Lysenko OA
    Lik Sprava; 2007; (5-6):111-7. PubMed ID: 18416173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease.
    Koifman B; Topilski I; Megidish R; Zelmanovich L; Chernihovsky T; Bykhovsy E; Keren G
    Am J Cardiol; 2006 Jul; 98(2):172-7. PubMed ID: 16828587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of lozartan in patients with chronic cor pulmonale].
    Butorov IV; Butorov SI
    Klin Med (Mosk); 2005; 83(7):65-9. PubMed ID: 16117431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats.
    Janic M; Lunder M; Cerne D; Marc J; Jerin A; Skitek M; Drevensek G; Sabovic M
    J Cardiovasc Pharmacol; 2016 Jul; 68(1):74-80. PubMed ID: 27010807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of ACE inhibition on coronary endothelial dysfunction.
    Nickenig G; Stäblein A; Wassmann S; Wyen C; Müller C; Böhm M
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):361-4. PubMed ID: 11967824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats.
    Matsumoto T; Ishida K; Nakayama N; Taguchi K; Kobayashi T; Kamata K
    Pharmacol Res; 2010 Sep; 62(3):271-81. PubMed ID: 20304070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blockers of angiotensin receptors: a novel approach to the treatment of secondary pulmonary hypertension].
    Butorov IV; Verbitskiĭ ON; Butorov SI
    Ter Arkh; 2004; 76(6):84-7. PubMed ID: 15332584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
    Bayorh MA; Ganafa AA; Eatman D; Walton M; Feuerstein GZ
    Am J Hypertens; 2005 Nov; 18(11):1496-502. PubMed ID: 16280288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
    Yavuz D; Koç M; Toprak A; Akpinar I; Velioğlu A; Deyneli O; Haklar G; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):197-203. PubMed ID: 14608527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes.
    Cheetham C; O'Driscoll G; Stanton K; Taylor R; Green D
    Clin Sci (Lond); 2001 Jan; 100(1):13-7. PubMed ID: 11115412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects of endothelial dysfunction reversion in patients with congestive heart failure].
    Vizir VA; Berezin AE
    Klin Med (Mosk); 2000; 78(7):36-9. PubMed ID: 10979640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease.
    Landmesser U; Spiekermann S; Preuss C; Sorrentino S; Fischer D; Manes C; Mueller M; Drexler H
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):943-8. PubMed ID: 17234726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension.
    Chung NA; Beevers DG; Lip G
    Blood Press; 2004; 13(3):183-9. PubMed ID: 15223728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients.
    Kjaer A; Kristoffersen US; Tarnow L; Parving HH; Hesse B
    Diabetes Res Clin Pract; 2009 Apr; 84(1):34-8. PubMed ID: 19233497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
    Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion.
    Preumont N; Unger P; Goldman S; Berkenboom G
    Cardiovasc Drugs Ther; 2004 May; 18(3):197-202. PubMed ID: 15229387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
    Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
    J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.
    Watanabe T; Suzuki J; Yamawaki H; Sharma VK; Sheu SS; Berk BC
    Circulation; 2005 Sep; 112(12):1798-805. PubMed ID: 16172287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.